Related Links Educational Materials About Clinical Trials Clinical Trials: Questions and Answers Questions to Ask Your Doctor Drug Information from MedlinePlus

Alternate Title
Basic Trial Information
Trial Description
     Purpose
     Eligibility
     Treatment/Intervention
Trial Contact Information
Registry Information

Alternate Title

Phase II Study of Induction Chemotherapy Comprising Carboplatin and Docetaxel Followed by Radiotherapy and Consolidation Chemotherapy Comprising Carboplatin and Docetaxel in Patients With Stage III or IV or Recurrent Endometrial Cancer

Basic Trial Information

Phase	Type	Status	Age	Sponsor	Protocol IDs
Phase II	Treatment	Active	18 and over	NCI	UMN-2004LS021 UMN-WCC-38, NCT00258362

Trial Description

Purpose:

Drugs used in chemotherapy, such as carboplatin and docetaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) may kill more tumor cells. Radiation therapy uses high-energy x-rays to kill tumor cells. Giving combination chemotherapy together with radiation therapy may kill more tumor cells.

This phase II trial is studying how well giving carboplatin and docetaxel followed by radiation therapy works in treating patients with stage III, stage IV, or recurrent endometrial cancer.

Eligibility:

Eligibility criteria include the following:

• At least 18 years old
• No previous chemotherapy or radiation therapy
• For more information about the eligibility criteria for this trial, refer to the Health Professional version.

Final eligibility for a clinical trial is determined by the health professionals conducting the trial.

Treatment/Intervention:

Patients will receive a 1-hour infusion of docetaxel and an infusion of carboplatin. Treatment may repeat every 3 weeks for three courses. They will later undergo radiation therapy 5 days a week for up to 7 weeks. Beginning 3-4 weeks later, patients will receive three more courses of docetaxel and carboplatin.

After finishing treatment, patients will be evaluated periodically for 2 years.

Important:

For more details about this trial, refer to the Health Professional version of the trial summary.

If you are interested in participating in a clinical trial, contact your doctor for a referral or call a trial contact person listed below. You may see the same contact person listed at more than one site, however, if you call the number listed you can ask to speak to the study coordinator or person involved with the specific trial you are interested in. If you have questions about cancer or clinical trials, call the Cancer Information Service at 1-800-4-CANCER (1-800-422-6237). General information about clinical trials, including risks, benefits, and costs, can be found on NCI's Web site.

Trial Contact Information

Trial Lead Organizations

Masonic Cancer Center at University of Minnesota

Melissa Geller, MD, Principal investigator		Ph: 612-626-3111; 888-226-2376

U.S.A.
Minnesota
	Minneapolis
	Masonic Cancer Center at University of Minnesota
		Clinical Trials Office - Masonic Cancer Center at University of Minnesota	Ph:  612-624-2620
	St. Louis Park
	Park Nicollet Cancer Center
		Rahel Ghebre, MD	Ph:  952-993-6705

Registry Information
Official Title		A Phase II Trial of Induction Carboplatin and Docetaxel Followed by Radiotherapy then Consolidation Chemotherapy with Carboplatin and Docetaxel in Stage III, IV and Recurrent Endometrial Cancer
Trial Start Date		2005-07-22
Trial Completion Date		2009-08-01 (estimated)
Registered in ClinicalTrials.gov		NCT00258362
Date Submitted to PDQ		2005-10-05
Information Last Verified		2009-01-18
NCI Grant/Contract Number		CA77598